Why now

Although the approval was earlier in June, this is still worth enriching because it is a real regulatory milestone in an aggressive cancer with poor options after platinum therapy. The better why-now is not 'Europe approved a drug.' It is that Amgen's DLL3-targeting T-cell engager moved into a defined EU post-platinum extensive-stage small cell lung cancer setting, backed by Phase 3 DeLLphi-304 survival data, and should now be tracked for access, toxicity management, and real-world uptake.